Synexus focuses on mild cognitive impairment studies

Mild cognitive impairment (MCI) is under the pharmaceutical spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus, a UK-based patient recruitment and trial management business, has teamed up with dementia expert, Roger Bullock, to develop more effective clinical trials for this field.

Synexus, headquartered in Manchester, UK, claims it is the world’s largest multinational company dedicated to the recruitment and running of clinical trials at its own research centers across the globe on behalf of its pharmaceutical, biotechnology and contract research organization clients. Synexus now has 26 dedicated research centers across the UK, Germany, Austria, Poland, Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time Good Clinical Practice (GCP)-trained investigators.

Dr Bullock has over 10 year’s clinical trials experience in the field of dementia and is committed to this work as a vital part of the research that will ultimately benefit millions of people worldwide. Christophe Berthoux, Synexus’ chief executive, said:“Dr Bullock is widely recognized for his clinical trials work in mild cognitive impairment (MCI). We are really excited about teaming up with him to start delivering more effective and faster clinical trials in this area. The financial cost of dementia across the world is set to take off. So not only do we need to address the serious health and quality of life implications of these conditions, we also need to tackle the massive financial burden as a matter of urgency.”